ProMIS NeurosciencesProMIS Neurosciences
  • Home
  • Company
  • Team
  • Advisory Boards
  • Product Portfolio
  • Investors
  • News & Media
  • Contact

    The ProMIS Neurosciences Annual General Meeting will take place:
    9:00 a.m. (Pacific Time) on July 29, 2020
    Suite 1500, 1055 West Georgia Street,
    Vancouver, British Columbia
    . 

    1. Financial statement request form
    2. Notice of Annual meeting
    3.  Proxy
    4.  Financial Statements & MD&A
    5. Circular

    Investor Quick LInks

    • Investors
    • Fact Sheet, updated Nov. 9th 2020
    • SEDAR Filings
    • AGM 2020
    • Policies and Compliance

    Analyst Coverage

    • Caroline Palomeque
      Maxim Group
    • John Vandermosten, CFA
      Zacks

    Stock Ticker

    TSX symbol: PMN.TO

    OTCQB symbol: ARFXF

    Subscribe

    Subscribe to our mailing list

    Company News

    • ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field February 2, 2021
    • ProMIS Neurosciences Announces Strategic Priorities  for 2021 January 12, 2021
    • YEAR IN REVIEW, LOOKING FORWARD TO 2021 December 14, 2020

    Scientific Presentations

    • Sachs Neuroscience Innovation Forum Presentation January 27, 2020
    • ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform November 6, 2019
    • Executive Chairman Gene William’s Presentation at the HC Wainwright Investor Conference September 10, 2019

    About

    ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the Toronto Stock Exchange (ticker symbol: PMN.TO) and OTCQB (ticker symbol: ARFXF).ProMIS is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

    Subscribe

    Subscribe to our mailing list

    Privacy Policy

    Privacy Policy

    Company News

    • ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field February 2, 2021
    • ProMIS Neurosciences Announces Strategic Priorities  for 2021 January 12, 2021
    • YEAR IN REVIEW, LOOKING FORWARD TO 2021 December 14, 2020

    Contact

    ProMIS™ Neurosciences, Inc.
    1920 Yonge Street
    Suite 200
    Toronto, ON M4S 3E2
    Email ProMIS

    Stock Ticker

    Traded on the Toronto Stock Exchange (TSX), under the symbol PMN.TO, and on the OTCQB under the symbol ARFXF

    © 2021 ProMIS Neurosciences. • Site Design by StudioTwo.com

    • Home
    • Company
    • Team
    • Advisory Boards
    • Product Portfolio
    • Investors
    • News & Media
    • Contact